Robin Kroll

2.7k total citations · 1 hit paper
40 papers, 1.6k citations indexed

About

Robin Kroll is a scholar working on Public Health, Environmental and Occupational Health, Endocrinology, Diabetes and Metabolism and Reproductive Medicine. According to data from OpenAlex, Robin Kroll has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Public Health, Environmental and Occupational Health, 12 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Reproductive Medicine. Recurrent topics in Robin Kroll's work include Reproductive Health and Contraception (12 papers), Menopause: Health Impacts and Treatments (12 papers) and Sexual function and dysfunction studies (7 papers). Robin Kroll is often cited by papers focused on Reproductive Health and Contraception (12 papers), Menopause: Health Impacts and Treatments (12 papers) and Sexual function and dysfunction studies (7 papers). Robin Kroll collaborates with scholars based in United States, United Kingdom and Australia. Robin Kroll's co-authors include Céline Bouchard, Cynthia Rodenberg, Susan R. Davis, Michèle Moreau, Arthur Waldbaum, Andrea J. Rapkin, Simon Pack, Nick Panay, Helga Koch and Alain Moufarege and has published in prestigious journals such as New England Journal of Medicine, The Lancet Neurology and The Journal of Infectious Diseases.

In The Last Decade

Robin Kroll

38 papers receiving 1.5k citations

Hit Papers

Safety and efficacy of ALD403, an antibody to calcitonin ... 2014 2026 2018 2022 2014 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
    2014 299 citations David W. Dodick, Peter J. Goadsby et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Kroll United States 16 746 713 362 330 303 40 1.6k
J. W. W. Studd United Kingdom 20 172 0.2× 624 0.9× 231 0.6× 608 1.8× 356 1.2× 61 1.8k
Ricardo Munarriz United States 30 1.8k 2.4× 1.1k 1.5× 61 0.2× 349 1.1× 291 1.0× 120 2.6k
Brinda Wiita United States 16 300 0.4× 808 1.1× 113 0.3× 113 0.3× 191 0.6× 27 1.5k
J. J. J. Waelkens Netherlands 22 220 0.3× 811 1.1× 154 0.4× 109 0.3× 277 0.9× 40 1.5k
Luisa Petrone Italy 26 1.4k 1.9× 1.7k 2.3× 74 0.2× 93 0.3× 320 1.1× 60 2.4k
Susan Kellogg‐Spadt United States 15 626 0.8× 268 0.4× 40 0.1× 222 0.7× 161 0.5× 33 1.2k
Rosana Maria dos Reis Brazil 29 209 0.3× 425 0.6× 35 0.1× 980 3.0× 1.6k 5.2× 146 2.5k
Lori Hollander United States 10 95 0.1× 599 0.8× 171 0.5× 322 1.0× 173 0.6× 16 1.0k
S Rosberg Sweden 24 99 0.1× 1.0k 1.4× 39 0.1× 117 0.4× 131 0.4× 47 1.9k
A. C. Drogendijk Netherlands 20 106 0.1× 212 0.3× 76 0.2× 433 1.3× 374 1.2× 50 1.4k

Countries citing papers authored by Robin Kroll

Since Specialization
Citations

This map shows the geographic impact of Robin Kroll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Kroll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Kroll more than expected).

Fields of papers citing papers by Robin Kroll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Kroll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Kroll. The network helps show where Robin Kroll may publish in the future.

Co-authorship network of co-authors of Robin Kroll

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Kroll. A scholar is included among the top collaborators of Robin Kroll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Kroll. Robin Kroll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miller, Charles E., Jin Hee Kim, Robin Kroll, et al.. (2024). Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial. American Journal of Obstetrics and Gynecology. 231(6). 630.e1–630.e13. 9 indexed citations
2.
Brown, Eric L., Robin Kroll, Juki Ng, et al.. (2023). Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas. Obstetrics and Gynecology. 142(5). 1068–1076. 1 indexed citations
3.
Fraser, Graeme L., Samuel Lederman, Arthur Waldbaum, et al.. (2020). A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause The Journal of The North American Menopause Society. 27(4). 382–392. 75 indexed citations
4.
Standaert, Baudouin, Stephan Bart, Laurence Chu, et al.. (2019). Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study. Health and Quality of Life Outcomes. 17(1). 80–80. 8 indexed citations
5.
Liu, James, David E. Soper, Andrea S. Lukes, et al.. (2018). Ulipristal Acetate for Treatment of Uterine Leiomyomas. Obstetrics and Gynecology. 132(5). 1241–1251. 30 indexed citations
6.
Kroll, Robin, David F. Archer, Yu‐Hua Lin, Vilma Sniukiene, & James Liu. (2017). A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause The Journal of The North American Menopause Society. 25(2). 133–138. 29 indexed citations
7.
Kingsberg, Sheryl A., Robin Kroll, Irwin Goldstein, et al.. (2017). 013 Product Acceptability and Women's Satisfaction with a Low-dose Solubilized Vaginal Estradiol Softgel Capsule, TX-004H. The Journal of Sexual Medicine. 14(Supplement_5). e355–e355. 1 indexed citations
8.
9.
Segall, Nathan, Murdo Ferguson, Louise Frenette, et al.. (2016). Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. The Journal of Infectious Diseases. 214(11). 1717–1727. 37 indexed citations
10.
Seidman, Larry, et al.. (2015). Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. Contraception. 91(6). 495–502. 12 indexed citations
11.
Kroll, Robin, et al.. (2015). Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol. Contraception. 93(3). 249–256. 6 indexed citations
12.
Dodick, David W., Peter J. Goadsby, Stephen D. Silberstein, et al.. (2014). Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. The Lancet Neurology. 13(11). 1100–1107. 299 indexed citations breakdown →
13.
Kroll, Robin, et al.. (2014). A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. The European Journal of Contraception & Reproductive Health Care. 20(4). 249–258. 11 indexed citations
14.
Merz, Martin, Robin Kroll, R. Lynen, & Keith Bangerter. (2014). Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. Contraception. 91(2). 113–120. 7 indexed citations
15.
Kroll, Robin, et al.. (2009). The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 81(1). 41–48. 27 indexed citations
16.
Imani, Reza, et al.. (2009). Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis. Fertility and Sterility. 92(3). S111–S112. 6 indexed citations
17.
Davis, Susan R., Michèle Moreau, Robin Kroll, et al.. (2008). Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. New England Journal of Medicine. 359(19). 2005–2017. 304 indexed citations
18.
Davis, Anne, et al.. (2007). Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertility and Sterility. 89(5). 1059–1063. 22 indexed citations
19.
Shifren, Jan L., Susan R. Davis, Michèle Moreau, et al.. (2006). Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women. Menopause The Journal of The North American Menopause Society. 13(5). 770–779. 226 indexed citations
20.
Freeman, Ellen W., Robin Kroll, Andrea J. Rapkin, et al.. (2001). Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder. Journal of Women s Health & Gender-Based Medicine. 10(6). 561–569. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. W. W. Studd Breakdown of academic impact, for papers by Ricardo Munarriz Breakdown of academic impact, for papers by Brinda Wiita Breakdown of academic impact, for papers by J. J. J. Waelkens Breakdown of academic impact, for papers by Luisa Petrone Breakdown of academic impact, for papers by Susan Kellogg‐Spadt Breakdown of academic impact, for papers by Rosana Maria dos Reis Breakdown of academic impact, for papers by Lori Hollander Breakdown of academic impact, for papers by S Rosberg Breakdown of academic impact, for papers by A. C. Drogendijk
Rankless by CCL
2026